TY - JOUR
T1 - Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission
AU - Nibourel, Olivier
AU - Kosmider, Olivier
AU - Cheok, Meyling
AU - Boissel, Nicolas
AU - Renneville, Aline
AU - Philippe, Nathalie
AU - Dombret, Hervé
AU - Dreyfus, François
AU - Quesnel, Bruno
AU - Geffroy, Sandrine
AU - Quentin, Samuel
AU - Roche-Lestienne, Catherine
AU - Cayuela, Jean Michel
AU - Roumier, Christophe
AU - Fenaux, Pierre
AU - Vainchenker, William
AU - Bernard, Olivier A.
AU - Soulier, Jean
AU - Fontenay, Michaëla
AU - Preudhomme, Claude
PY - 2010/8/19
Y1 - 2010/8/19
N2 - Mutations of the ten eleven translocation 2 gene (TET2) have recently been reported in myelodysplastic syndrome and myeloproliferative neoplasms. We analyzed the incidence and prognostic value of TET2 point mutations and other genomic alterations by direct sequencing and single nucleotide polymorphism microarray analysis in 111 de novo acute myeloid leukemia, who had all achieved complete remission (CR). Mutations were observed in 19 (17%) of the 111 patients compared with 10 (27%) of 36 patients who had failed to achieve CR (P = .2). In the 111 patients who had achieved CR, TET2 alterations were only significantly associated with NPM1 mutations but not with other pretreatment characteristics. TET2 gene status was not significantly correlated with disease-free survival and overall survival, both in the entire cohort and in patients with normal karyotype.
AB - Mutations of the ten eleven translocation 2 gene (TET2) have recently been reported in myelodysplastic syndrome and myeloproliferative neoplasms. We analyzed the incidence and prognostic value of TET2 point mutations and other genomic alterations by direct sequencing and single nucleotide polymorphism microarray analysis in 111 de novo acute myeloid leukemia, who had all achieved complete remission (CR). Mutations were observed in 19 (17%) of the 111 patients compared with 10 (27%) of 36 patients who had failed to achieve CR (P = .2). In the 111 patients who had achieved CR, TET2 alterations were only significantly associated with NPM1 mutations but not with other pretreatment characteristics. TET2 gene status was not significantly correlated with disease-free survival and overall survival, both in the entire cohort and in patients with normal karyotype.
UR - http://www.scopus.com/inward/record.url?scp=77956513784&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-07-234484
DO - 10.1182/blood-2009-07-234484
M3 - Article
C2 - 20489055
AN - SCOPUS:77956513784
SN - 0006-4971
VL - 116
SP - 1132
EP - 1135
JO - Blood
JF - Blood
IS - 7
ER -